Sign in

    Dennis Resnick

    Research Analyst at Raymond James

    Dennis Resnick is an Analyst at Raymond James specializing in biotechnology and pharmaceutical equity research, with direct coverage of emerging life sciences companies such as Lenz Therapeutics and INmune Bio. He is known for providing actionable insights and in-depth analysis during earnings calls, leveraging keen familiarity with regulatory and FDA dynamics affecting his coverage universe. Resnick has advanced within Raymond James’s healthcare equity research group, participating in high-visibility events and company updates since joining the firm, with prior experience and specific career history details not publicly available. He holds applicable securities industry credentials required for his analyst role, though individual license types and FINRA registration specifics are currently undisclosed.

    Dennis Resnick's questions to Bausch & Lomb (BLCO) leadership

    Dennis Resnick's questions to Bausch & Lomb (BLCO) leadership • Q4 2024

    Question

    Dennis Resnick, on for Gary Nachman, asked about the dry eye franchise, requesting metrics on patient compliance and refill rates for Miebo. He also inquired about the conversion efforts from sampling the larger 1.6 mL bottle and its impact on activating new prescribers.

    Answer

    Chairman and CEO Brenton L. Saunders explained that a key differentiator for Miebo is its significantly higher refill rate compared to other drugs in the category, which he attributed to its strong clinical and safety profile. He described it as a 'stickier' and 'harder working' prescription, which supports the long-term investment and outlook for the product. He did not provide specific metrics on the 1.6 mL bottle conversion.

    Ask Fintool Equity Research AI